KCM
SNDX icon

Kennedy Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Kennedy Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-78,083
Closed -$1.49M – 638
2021
Q3 		$1.49M Buy
+78,083
New +$1.3M 0.03% 491

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kennedy Capital Management's SNDX Position: Q4 2021 in Review

Kennedy Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2021, closing a stake of 78,083 shares — an estimated $1.49M sold.

Kennedy Capital Management first reported a position in SNDX in Q3 2021 and held it in 1 quarter. The position peaked at $1.49M in Q3 2021. 132 funds tracked by Wall St. Rank hold SNDX as of Q4 2021.

  • Kennedy Capital Management reported no remaining Syndax Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Kennedy Capital Management sold 78,083 Syndax Pharmaceuticals shares in Q4 2021, an estimated $1.49M.
  • Kennedy Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Kennedy Capital Management's Syndax Pharmaceuticals position peaked at $1.49M in Q3 2021.
  • 132 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2021.

Based on Kennedy Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.